Sars-CoV2 Clinical Trial
— SEROPHUGACOfficial title:
Serological Study of the Exposure of Personnel to Sars-cov-2 in an Urban Hospital Two Months After Managing an Influx of COVID Patients 19
| NCT number | NCT04422977 |
| Other study ID # | SEROPHUGAC |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | June 8, 2020 |
| Est. completion date | July 10, 2020 |
| Verified date | April 2024 |
| Source | Centre Hospitalier Saint Joseph Saint Luc de Lyon |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
A seroconversion test for SARS-Cov-2 will be offered to all the employees of a care institution, which has treated 240 patients hospitalized for COVID disease between 28/02 and 30/04/2020. The seroconversion test will be with a questionnaire to determine: - whether the subject has shown signs of infection in the last 3 recent months - if the subject has been in contact with COVID-diagnosed subjects (RT-PCR diagnosis or scanner) outside of the activity or within the professional activity (patient or colleague) - Working conditions during the period - The level of knowledge and respect of the barrier measures practices. - Respect for distance during meals professional. Overall seroprevalence and stratified seroprevalence by care and administrative areas will be determined.
| Status | Completed |
| Enrollment | 957 |
| Est. completion date | July 10, 2020 |
| Est. primary completion date | July 10, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility | Inclusion Criteria: - Subject who worked at Saint Joseph Saint Luke's Hospital during the epidemic wave (male or female). - Free and informed consent - Social security affiliation Exclusion Criteria: - Subject refusal - Subject on leave during the entire period |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre Hospitalier St Joseph St Luc | Lyon |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Saint Joseph Saint Luc de Lyon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff with a seroconversion test for SARS-Cov-2 | Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff | 1 month |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04446065 -
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
|
Phase 2/Phase 3 | |
| Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
| Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
| Completed |
NCT04463004 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 | |
| Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
| Recruiting |
NCT04441372 -
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
|
||
| Recruiting |
NCT04581148 -
SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
|
||
| Completed |
NCT04530604 -
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
|
Phase 1 | |
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Active, not recruiting |
NCT04635605 -
Methylene Blue Treatment of COVID-19
|
Phase 2 | |
| Recruiting |
NCT04395599 -
Risk of Air Contamination During Visceral Surgery in COVID19 Patients
|
N/A | |
| Recruiting |
NCT04472585 -
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04411433 -
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
|
Phase 3 | |
| Completed |
NCT04359706 -
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
|
||
| Recruiting |
NCT04395794 -
SARS-CoV-2 Disguise Study
|
||
| Completed |
NCT04386551 -
Detection of COVID-19 in Saliva Collection
|
||
| Recruiting |
NCT04403269 -
NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE
|
Phase 2 | |
| Withdrawn |
NCT04379492 -
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
|
Phase 2 | |
| Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|